Biden’s HHS Pick Sought ‘March In’ Rights For Veklury; Targeted AbbVie ‘Pay For Delay’ Tactics
California attorney general Xavier Becerra has sought to lower drug prices in California as part of a broader focus on health care costs, an approach he may bring to a new role in the Biden Administration.
You may also be interested in...
After increasing his drug pricing-related complaints, the HELP committee chair opposed Bertagnolli becoming NIH director, but a bipartisan group of senators voted 15-6 in favor of moving her nomination to the full Senate.
NIH Nominee Says Americans Deserve ‘Return On Investment’ Via Affordable Meds, But Offers No Implementation Plan
Monica Bertagnolli angered Senators on both sides of the pricing debate during her confirmation hearing when said she would execute a plan to ensure the benefits of NIH research are affordable and available to all Americans but couldn’t offer any specifics on how she would achieve it.
Market availability of Xtandi, not its cost, is the issue, NIH says in denying petition for government to invoke march-in rights to patents on the prostate cancer drug. But Biden administration makes two other same-day moves that could leave march-in advocates with some hope.